shutterstock_1595586766_ken_wolter
Ken Wolter / Shutterstock.com
6 March 2020Big PharmaClaire Irvine

Broad Institute down (but not out) in the European fight over CRISPR IP

Following the upholding in January 2020 of the revocation of the Broad Institute’s lead European patent (EP 2771468) by a European Patent Office (EPO) Appeal Board, there has been speculation that the University of California and its co-applicants (UC) have the upper hand in the European fight over the IP of clustered regularly interspaced short palindromic repeats (more commonly known as ‘CRISPR’), the latest incarnation of genome editing and deliberate alteration.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
16 January 2020   In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

More on this story

Europe
16 January 2020   In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

More on this story

Europe
16 January 2020   In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.